Leerink Partners Reiterates Outperform Rating on Ultragenyx Pharma (RARE): "encouraged by this clinical win"
Leerink Partners analyst Joseph Schwartz reiterated an Outperform rating and $60.00 price target on Ultragenyx Pharma (NASDAQ: RARE)The analyst commented ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)